You are here
Neumedicines Inc.
UEI: N/A
# of Employees: 26
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
A Phase IIa Study of rHuIL-12 as an Immunotherapy and Radiomitigator for CTCL Patients Receiving Radiotherapy
Amount: $1,505,508.00DESCRIPTION provided by applicant Cutaneous T cell lymphoma CTCL is a chronic incurable disease with significant morbidity and mortality Treatment of CTCL depends on clinical stage and include ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
IL-12-Faciliated Hematopoietic Recovery Following Myeloablative Therapy
Amount: $197,568.00DESCRIPTION (provided by applicant): Intensive myeloablative cytotoxic treatment followed by autologous hematopoietic stem cell transplantation (HSCT) is frequently used in clinical practice to cure o ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health -
Retroviral Vectors for Safe and Efficacious Gene Therapy
Amount: $1,002,076.00DESCRIPTION (provided by applicant): Phase I funding for this project supported the successful development of the backbone for a new generation of retroviral gene therapy vectors that contain safety a ...
STTRPhase II2006Department of Health and Human Services National Institutes of Health -
Retroviral Vectors for Safe and Efficacious Gene Therapy
Amount: $1,002,080.00DESCRIPTION (provided by applicant): Phase I funding for this project supported the successful development of the backbone for a new generation of retroviral gene therapy vectors that contain safety a ...
SBIRPhase II2006Department of Health and Human Services National Institutes of Health -
Retroviral Vectors for Safe and Efficacious Gene Therapy
Amount: $148,499.00DESCRIPTION (provided by applicant): The goal of this proposal is to engineer safer more efficacious vectors for use in human gene therapy. The development of safer and more efficient retroviral vecto ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy
Amount: $599,998.00DESCRIPTION (provided by applicant): The long term and overall goal of the proposed Phase I and Phase II studies is to develop the commercial use of Interleukin-12 (IL-12) as a hematological adjuvant ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
Retroviral Vectors for Safe and Efficacious Gene Therapy
Amount: $148,499.00DESCRIPTION (provided by applicant): The goal of this proposal is to engineer safer more efficacious vectors for use in human gene therapy. The development of safer and more efficient retroviral vecto ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy
Amount: $599,998.00DESCRIPTION (provided by applicant): The long term and overall goal of the proposed Phase I and Phase II studies is to develop the commercial use of Interleukin-12 (IL-12) as a hematological adjuvant ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health
